title: Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.
authors.affiliation: Mount Sinai School of Medicine, New York, NY 10029-6574, USA. louis.aledort@mssm.edu
authors.forename: L M
authors.initials: LM
authors.lastname: Aledort
mesh_terms: D000818:Animals; D001779:Blood Coagulation Factors / Q000276:immunology*; D006801:Humans; D015994:Incidence; D007518:Isoantibodies / Q000097:blood*; D015995:Prevalence; D011994:Recombinant Proteins / Q000276:immunology*; D012307:Risk Factors
chemical_list: D001779:Blood Coagulation Factors; D007518:Isoantibodies; D011994:Recombinant Proteins